galcanezumab

Home
Ligands
galcanezumab

GtoPdb Ligand ID: 8967

Synonyms: clone III | Emgality® | galcanezumab-gnlm | LY-2951742 | LY2951742

galcanezumab is an approved drug (FDA (2018))

Comment: Galcanezumab (LY2951742) is a monoclonal antibody targeting calcitonin A and B (CALCA a.k.a. α-CGRP and CALCB a.k.a. β-CGRP respectively), whose anti-migraine and analgesic actions can be applied clinically.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record. Protein BLAST analysis reveals 100% matches with peptides claimed in patent WO2007076336 [1].

Summary
Biological activity
Clinical data
References
Immunopharmacology

Immunopharmacology Comments
Galcanezumab acts as a CGRP-scavenger. We have included it in GtoImmuPdb as it targets the CGRP signalling pathway and so disrupts CGRP-mediated vasodilatory and pro-inflammatory actions.

Immunopharmacology Comments

Galcanezumab acts as a CGRP-scavenger. We have included it in GtoImmuPdb as it targets the CGRP signalling pathway and so disrupts CGRP-mediated vasodilatory and pro-inflammatory actions.